Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

- PMLiVE

AstraZeneca scores in final lung disease drug trials

The firm hopes it LAMA/LABA drug can take a big chunk from the $14bn COPD market

- PMLiVE

AstraZeneca’s heart drug impresses, but bleeding risks a concern

Firm still hopes the new Brilinta data can help the medicine be a blockbuster

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

Campaigns improve cancer symptom awareness, claims BJC

Has shown an increase in GP visits for possible cancer symptoms

- PMLiVE

AZ gets injunction to protect Pulmicort Respules

Actavis blocked from selling generic five days after AZ’s asthma launch

- PMLiVE

AstraZeneca employs Wolfram tech for liver health research

Project could produce mathematical models that can detect liver problems

- PMLiVE

Inventor turns bomb detector into cancer breathalyser

Clinical trials of Billy Boyle's device will be held in two NHS hospitals

- PMLiVE

MedImmune partners with university on protein formulation science

Four-year partnership to research antibodies and novel proteins

- PMLiVE

AZ adds to respiratory portfolio with Actavis drugs

Follows deal to acquire Almirall’s franchise in asthma and COPD

- PMLiVE

AZ and University of Texas to collaborate on cancer research

Studies will aim to improve patient outcomes

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links